# **Supplementary information:** Identifying target regions for enhanced control of gambiense human African trypanosomiasis in the Democratic Republic of Congo

Ching-I Huang<sup>a,b,\*</sup>, Ronald E Crump<sup>a,b,c,\*</sup>, Paul Brown<sup>a,b</sup>, Simon E F Spencer<sup>a,d</sup>, Erick Mwamba Miaka<sup>e</sup>, Chansy Shampa<sup>e</sup>, Matt J Keeling<sup>a,b,c</sup>, Kat S Rock<sup>a,b</sup>

<sup>a</sup>Zeeman Institute for System Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, U.K.

<sup>b</sup>Mathematics Institute, The University of Warwick, Coventry, U.K.

<sup>c</sup>The School of Life Sciences, The University of Warwick, Coventry, U.K.

<sup>d</sup>The Department of Statistics, The University of Warwick, Coventry, U.K.

<sup>e</sup>Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, D.R.C.

#### S1. Methods 1

This work is one of a series of studies on modelling and analyses on issues in the last mile of eliminating transmission 2

of gambiense human African trypanosomiasis (gHAT) in the Democratic Republic of Congo (DRC). The series of 3

studies starts with a model fitting paper<sup>1</sup> and to aid the reader of the present study, much of the same model information 4

is provided here in the Methods section. 5

#### S1.1. The compartmental gHAT model 6

The gHAT model we considered in this study is a variant "Model 4" of the Warwick model presented in the litera-7 ture<sup>1,2,3,4</sup>. gHAT infections among hosts are described by equation (S1). Human hosts are modelled by the SEIIRS 8 model with two infectious compartments, stage 1 disease,  $I_{1H}$ , and stage 2 disease,  $I_{2H}$ . Vectors are modelled by 9 using compartments for appropriately modelling tsetse when used in a host-vector model with disease<sup>3</sup>. Pupal stage 10 tsetse,  $P_V$ , emerge into unfed susceptible adults,  $S_V$ , and following a blood-meal become either exposed,  $E_V$ , or 11 have reduced susceptibility to the Trypanosoma brucei gambiense parasites,  $G_V$  - this effect is known as the teneral 12 phenomenon. Following an infection, tsetse have an extrinsic incubation period (EIP) before becoming onwardly 13 infectious. To incorporate a more realistic EIP distribution, there are three exposed classes,  $E_{1V}, E_{2V}, E_{3V}$ , which 14 result in a gamma-distributed EIP (rather than an exponential with only one). 15

In order to reduce the dimensionality of our ODE system (by one), the vector equations are non-dimensionalised using 16 the scaling  $N_H/N_V$ , where  $N_H$  is the total human population, and  $N_V$  is the tsetse population size. This results in 17

a new non-dimensionalised parameter,  $m_{\text{eff}}$ , which is  $\frac{\hat{p}_H N_V}{N_H}$  appearing in host equations ( $p_H$  is the probability of a

18

human being infected by a single infectious bloodmeal) and is referred to as the effective vector density. 19

The proportion of tsetse bites taken on low-risk and high-risk humans are  $f_1$  and  $f_4$ , depending on the relative avail-20

ability/attractiveness and the relative abundance of two risk groups. High-risk humans are assumed to be r-fold more 21

<sup>\*</sup>These authors contributed equally to this work. Email address: ching-i.huang@warwick.ac.uk (Ching-I Huang)

likely to receive bites, i.e.  $s_1 = 1$  and  $s_4 = r$ . Therefore,  $f_i$ 's can be calculated using  $f_i = \frac{s_i N_{Hi}}{\sum_j s_j N_{Hj}}$ .

$$\text{Humans} \begin{cases} \frac{dS_{Hi}}{dt} &= \mu_{H}N_{Hi} + \omega_{H}R_{Hi} - \alpha m_{\text{eff}}f_{i}\frac{S_{Hi}}{N_{Hi}}I_{V} - \mu_{H}S_{Hi} \\ \frac{dE_{Hi}}{dt} &= \alpha m_{\text{eff}}f_{i}\frac{S_{Hi}}{N_{Hi}}I_{V} - (\sigma_{H} + \mu_{H})E_{Hi} \\ \frac{dI_{1Hi}}{dt} &= \sigma_{H}E_{Hi} - (\varphi_{H} + \eta_{H}(Y) + \mu_{H})I_{1Hi} \\ \frac{dI_{2Hi}}{dt} &= \varphi_{H}I_{1Hi} - (\gamma_{H}(Y) + \mu_{H})I_{2Hi} \\ \frac{dR_{Hi}}{dt} &= \eta_{H}(Y)I_{1Hi} + \gamma_{H}(Y)I_{2Hi} - (\omega_{H} + \mu_{H})R_{Hi} \\ \end{cases} \\ \begin{cases} \frac{dP_{V}}{dt} &= B_{V}N_{H} - (\xi_{V} + \frac{P_{V}}{K})P_{V} \\ \frac{dS_{V}}{dt} &= \xi_{V}\mathbb{P}(\text{survive pupal stage})P_{V} - \alpha S_{V} - \mu_{V}S_{V} \\ \frac{dE_{1V}}{dt} &= \alpha(1 - f_{T}(t))p_{V}(\sum_{i}f_{i}\frac{(I_{1Hi} + I_{2Hi})}{N_{Hi}} + f_{A}\frac{I_{A}}{N_{A}})(S_{V} + \varepsilon G_{V}) \\ &- (3\sigma_{V} + \mu_{V} + \alpha f_{T}(t))E_{1V} \\ \frac{dE_{2V}}{dt} &= 3\sigma_{V}E_{1V} - (3\sigma_{V} + \mu_{V} + \alpha f_{T}(t))E_{2V} \\ \frac{dE_{3V}}{dt} &= 3\sigma_{V}E_{3V} - (\mu_{V} + \alpha f_{T}(t))E_{3V} \\ \frac{dI_{V}}{dt} &= 3\sigma_{V}E_{3V} - (\mu_{V} + \alpha f_{T}(t))I_{V} \\ \frac{dG_{V}}{dt} &= \alpha(1 - f_{T}(t))S_{V} \\ &- \alpha(f_{T}(t) + (1 - f_{T}(t))p_{V}\varepsilon(\sum_{i}f_{i}\frac{(I_{1Hi} + I_{2Hi})}{N_{Hi}} + f_{A}\frac{I_{A}}{N_{A}})G_{V}) \\ &- \mu_{V}G_{V} \end{cases} \end{cases}$$

# 23 *S1.2. Model assumptions and parameterisation*

<sup>24</sup> Table S1 provides the estimates of fixed parameters available in the literature used in the previous gHAT model<sup>1,2,3</sup>.

<sup>25</sup> The parameters fitted during the model fitting are defined in Table S2. Posterior distributions for these parameters

were based on the model fitting results<sup>1</sup>.

### 27 S1.3. Active screening

Screening data is aggregated by year and the exact dates and frequencies of conducting AS are unknown, therefore some assumptions were made on when AS takes place. Our model assumed only low-risk humans participate in AS and used the ratio of assumed number of people screened  $(N_{AS})$  and the number of low-risk humans  $(k_1N_H)$  to decide the frequency of AS each year. When screening numbers were smaller than potential participants  $(N_{AS} < k_1N_H)$ , a single AS event was assumed to take place at the beginning of those years. On the other hand, multiple AS events were evenly distributed over the time of the corresponding years, i.e. a second AS event in July when  $k_1N_H < N_{AS} \le 2k_1N_H$ ; a second AS event in May and a third AS event in September when  $2k_1N_H < N_{AS} \le 3k_1N_H$ ; etc.

# <sup>35</sup> S1.4. Formulation and parameterisation of improved passive detections in Bandundu and Bas Congo

<sup>36</sup> Previous analysis on provincial-level staged data (Lumbala *et al.* for 2000–2012<sup>16</sup> and WHO HAT Atlas data 2015–

<sup>37</sup> 2016<sup>17</sup>) indicated that improved passive detection has happened across former Bandundu province and in former Bas

Notation	Description	Value	
$N_H$	Total human population size	Fixed for each health zone	5
	in 2015		
$\mu_H$	Natural human mortality rate	$5.4795 \times 10^{-5} \text{ days}^{-1}$	6
$B_H$	Total human birth rate	$=\mu_H N_H$	
$\sigma_H$	Human incubation rate	$0.0833 \rm ~days^{-1}$	7
$\varphi_H$	Stage 1 to 2 progression rate	$0.0019 \rm ~days^{-1}$	8,9
$\omega_H$	Recovery rate or waning-immunity	$0.006  \rm days^{-1}$	10
	rate		
Sens	Active screening diagnostic	0.91	11
	sensitivity		
$B_V$	Tsetse birth rate	$0.0505 \rm ~days^{-1}$	3
$\xi_V$	Pupal death rate	0.037 days <sup>-1</sup>	
K	Pupal carrying capacity	$= 111.09 N_H$	3
$\mathbb{P}(\text{pupating})$	Probability of pupating	0.75	
$\mu_V$	Tsetse mortality rate	$0.03 \mathrm{~days^{-1}}$	7
$\sigma_V$	Tsetse incubation rate	$0.034 \mathrm{days}^{-1}$	2,13
α	Tsetse bite rate	$0.333  \rm days^{-1}$	14
$p_V$	Probability of tsetse infection	0.065	7
	per single infective bite		
ε	Reduced non-teneral susceptibility	0.05	2
	factor		
$f_H$	Proportion of blood-meals on	0.09	15
	humans		
disp <sub>act</sub>	Overdispersion parameter for	$4 \times 10^{-4}$	1
	active detection		
$\operatorname{disp}_{\operatorname{pass}}$	Overdispersion parameter for	$2.8 \times 10^{-5}$	1
<u> </u>	passive detection		

Table S1: Model parameterisation (fixed parameters). Notation, a brief description, and the used values for fixed parameters.

 $^1$  Value of  $B_V$  is chosen to maintain constant population size without interventions.  $^2$  Value of K is chosen to reflect the observed bounce back rate.

Notation	Description	Posterior (median [95% CI])		
		Kwamouth	Tandala	
$R_0$	Basic reproduction number	1.09	1.009	
	(NGM approach)	[1.06, 1.14]	[1.006, 1.014]	
r	Relative bites taken on	6.61	2.04	
	high-risk humans	[3.15, 10.75]	[1.30, 4.26]	
$k_1$	Proportion of low-risk people	0.90	0.95	
		[0.82, 0.95]	[0.85, 0.99]	
$\gamma_H^{\rm pre}$	Pre-1998 treatment rate	$1.72 \times 10^{-3}$	$2.53 \times 10^{-3}$	
	from stage 2 (days <sup><math>-1</math></sup> )	$[0.38, 4.88] \times 10^{-3}$	$[1.03, 7.15] \times 10^{-3}$	
$\eta_{H}^{ m post}$	Post-1998 treatment rate	$1.24 \times 10^{-4}$	$2.74 \times 10^{-4}$	
	from stage 1 (days <sup><math>-1</math></sup> )	$[0.60, 2.74] \times 10^{-4}$	$[1.11, 4.99] \times 10^{-4}$	
$\gamma_H^{\rm post}$	Post-1998 treatment rate	$1.88 \times 10^{-3}$	$3.60 \times 10^{-3}$	
	from stage 2 (days <sup><math>-1</math></sup> )	$[0.46, 5.42] \times 10^{-3}$	$[1.72, 8.98] \times 10^{-3}$	
Spec	Active screening diagnostic	0.9991	0.9998	
	specificity	[0.9987, 0.9997]	[0.9997, 0.9999]	
u	Proportion of stage 2	0.27	0.39	
	passive cases reported	[0.18, 0.40]	[0.29, 0.51]	
$d_{\text{change}}$	Midpoint year for passive	2005.8	-	
	improvement	[2004.4, 2007.3]		
$\eta_{H_{\mathrm{amp}}}$	Relative improvement in	2.52	-	
	passive stage 1 detection rate	[0.92, 5.46]		
$\gamma_{H_{\mathrm{amp}}}$	Relative improvement in	0.51	-	
	passive stage 2 detection rate	[0.24, 0.97]		
$d_{\text{steep}}$	Speed of improvement in	0.94	_	
	passive detection rate (years $^{-1}$ )	[0.68, 1.29]		

**Table S2: Model parameterisation (posteriors of fitted parameters).** Notation, a brief description, and representative percentiles of the posterior distributions for fitted parameters.

<sup>1</sup> See equation (S2) for improved passive detections formulated by  $d_{\text{change}}$ ,  $\eta_{H_{\text{amp}}}$ ,  $\gamma_{H_{\text{amp}}}$  and  $d_{\text{steep}}$ .

- <sup>38</sup> Congo province<sup>1</sup>. Logistic functions shown in equation (S2) were used to formulate the improved passive detections
- in Bandundu and Bas Congo in year Y.

$$\eta_H(Y) = \eta_H^{\text{post}} \left[ 1 + \frac{\eta_{H_{\text{amp}}}}{1 + \exp\left(-d_{\text{steep}}(Y - d_{\text{change}})\right)} \right],$$
  

$$\gamma_H(Y) = \gamma_H^{\text{post}} \left[ 1 + \frac{\gamma_{H_{\text{amp}}}}{1 + \exp\left(-d_{\text{steep}}(Y - d_{\text{change}})\right)} \right].$$
(S2)

<sup>40</sup> Parameter definitions and their posteriors are provided in Table S2. N.B. It was assumed that improvements in both

- stages shared the same midpoint year and speed of improvement within a health zone. However, the amplitude of
- variation in each health zone came from the fitting of health-zone-specific data.

#### 43 S1.5. Formulation and parameterisation of additional tsetse mortality under vector control measures

The function which describes the probability of both hitting a target and dying is time dependent (days) from when the targets where placed:

$$f_T(t) = f_{\max}\left(1 - \frac{1}{1 + \exp(-0.068(\operatorname{mod}(t, 182.5) - 127.75))}\right),$$
(S3)

and  $f_{\text{max}}$  is chosen such that the tsetse population after one year is at the observed/assumed percentage reduction. For

- the simplified model this is given by  $f_{\text{max}} = 0.0305$  for a 60% reduction,  $f_{\text{max}} = 0.0525$  for an 80% reduction, and
- $f_{\text{max}} = 0.0750$  for a 90% reduction.
- 47 S1.6. Simulations performed

Simulations were performed based on 1,000 model realisations. Observation uncertainty was considered by drawing ten random samples from the predicted mean dynamics for each set of parameters. A beta-binomial distribution in which an overdispersion parameter  $\rho$  was introduced to the binomial distribution was used to account for larger variance than the binomial. The probability of obtaining m successes out of n trials with probability p and overdispersion parameter  $\rho$  is

$$BetaBin(m; n, p, \rho) = \frac{\Gamma(n+1)\Gamma(m+a)\Gamma(n-m+b)\Gamma(a+b)}{\Gamma(n-m+1)\Gamma(n+a+b)\Gamma(a)\Gamma(b)},$$
(S4)

- 48 where  $a = p(1/\rho 1)$  and b = a(1-p)/p.
- <sup>49</sup> Main observable outputs including active and passive cases each year were predicted by 10,000 samples. Unobservable

<sup>50</sup> outputs, such as new infections and the year of EOT, were predicted directly from the 1,000 model realisations without <sup>51</sup> sampling (parameter uncertainty but no observation uncertainty). Our model also has the capability of outputting

<sup>52</sup> unreported deaths and person years spent in stage 1 and stage 2.

### 53 S1.7. Uncertainty

<sup>54</sup> Model predictions propagate parameter and observation uncertainty (see above). We tried to represent this uncertainty <sup>55</sup> in a variety of ways:

• Time series box plots were used to display statistical summaries of model predictions – the median (the middle line in each box), the lower and upper quartiles (the edges of each box showing 50% prediction intervals) and

<sup>58</sup> 95% prediction intervals (extended whiskers containing the middle 95% of outputs).

- The median of YEOT was used to indicate the estimated elimination year for a series of model predictions because neither extreme values (outliers) nor truncation of simulation will affect the estimates.
- Probability of EOT by 2030 (or any given year between 2020 and 2040 in GUI) was calculated as the proportion of model realisations that achieve EOT by 2030 or the given year. Its continuous spectrum shows how likely we are to achieve EOT by a particular year and highlights regions we are most uncertain about with respect to meeting this goal.
- Sensitivity analysis for VC was performed to provide additional assessment of the VC reduction assumption (see results below).

# 67 S1.8. Proxy for EOT

<sup>68</sup> The gHAT model we used here is a deterministic model described by ODEs with transition rates between compart-

<sup>69</sup> ments. In the deterministic model, variables such as new infections, new cases and deaths can be non-integer and their

values are continuous. The stochastic model, on the other hand, has dynamics driven by randomly occurring events

vith associated probabilities and its variables capture the discrete nature of the population. Despite good agreements

<sup>72</sup> on the mean dynamics in both models, even at very low prevalence, the dynamics at the endgame are different. Be-

- cause of the continuous nature of deterministic dynamics, the number of infected people asymptotes to zero rather
   than reaching it unlike the stochastic model. In this paper, an artificial EOT threshold i.e. one new infection per health
- <sup>74</sup> that reaching it time the stochastic model. In this paper, an artificial EOT the should her one meeting per hearth <sup>75</sup> zone per year was applied to new infections to determine whether EOT has been achieved or not. Other values of

<sup>76</sup> EOT thresholds, such as one new infection per 100,000 or per 1,000,000 people per year, can be found in the litera-

<sup>77</sup> ture<sup>18,19</sup>. Large variation in EOT threshold highlights the difficulty in choosing a proper threshold reflecting the reality.

<sup>78</sup> More detailed comparison between stochastic and deterministic model variants will be needed in the future to ensure

<sup>79</sup> robustness of year of EOT estimates arising from such a proxy threshold.

# 80 S2. Results

81 S2.1. Sensitivity analysis of the effectiveness of vector control

<sup>82</sup> The reported annual reductions in tsetse populations of vector control (VC) range from 80% to 99%<sup>4,20,21,22</sup>. The

reductions are highly variable between locations due to differences in accessibility and the effectiveness of target

deployments. In addition to the default tsetse reduction assumed here (80%), a conservative and a high but achievable reduction, 60% and 90%, are considered in the sensitivity analysis of VC. As shown in figure S1, the sensitivity

analysis shows that the effectiveness of VC has a direct impact on the numbers of underlying new infections and

<sup>87</sup> leading to a delay to EOT when VC effectiveness is low.



**Figure S1: Sensitivity analysis of vector control.** The reductions in tsetse populations depend on the accessibility and the effectiveness of target deployments. A conservative reduction (60%) and a high but achievable reduction (90%) are considered in the sensitivity analysis of VC. VC efficiently stops the transmission from tsetse to humans and therefore greatly reduces the number of new infections. The decreases in new infections reflect the effectiveness of vector control, i.e. 90% VC (dark purple and dark green) has fewer expected new infections than 60% VC (light purple and light green). As a result, time lags in achieving EOT for the less effective VC strategy are shown in both high-risk and low-risk health zones.

# 88 S3. Model Updates

Variations on this "Warwick gHAT model" have been published previously (see Section 1.1). Key differences between this model and previous versions (notably<sup>19</sup>) have been described in the study when the model was fitted to data<sup>1</sup> and are listed again here:

• Improved passive detection: Improvement due to the introduction of CATT test ( $\eta_H^{\text{pre}} = 0 \mapsto \eta_H^{\text{post}}$  and  $\gamma_H^{\text{pre}} = b_{\gamma_H^{\text{pre}}} \gamma_H^{\text{post}} \mapsto \gamma_H^{\text{post}}$  in Crump *et al*<sup>1</sup>) is considered in 1998 in the entire DRC as well as gradual improvements of stage 1 and stage 2 passive detection rates over time (see Subsection 1.4 above) are taken into account in Bandundu and Bas Congo provinces.

- MSF AS algorithm: The results of CATT 1:32, which has a higher sensitivity (MSF sensitivity = 0.95 in contrast to PNLTHA sensitivity = 0.91) and a lower fitted specificity (=  $b_{\text{specificity}} \times \text{specificity}$  with targeted mean = 0.991 in Crump *et al*<sup>1</sup>) than the PNLTHA-DRC algorithm, were used for case reporting and treatments in Orientale province in active screenings performed by MSF before 2013.
- Perfect specificity in AS: Video confirmation was introduced in Mosango and Yasa Bonga since 2015 and therefore the specificity in active screenings became 1 since then. Perfect specificity is also assumed in the rest of Bandundu from 2018.
- Overdispersion in case detections: Observation uncertainty is considered by adding overdispersion into case detections (see Subsection 1.6 above). To avoid overfitting, the overdispersion parameters were manually tuned to be appropriate for a health zone level fit, and thereafter left fixed across MCMC runs in Crump *et al*<sup>1</sup>.
- EOT threshold: A proxy threshold (= 1) of new infection per health zone per year is used to identify when EOT has been reached within this deterministic framework. Previous versions of this model have used a variety of proxy thresholds, typically fewer than one new infection per 100,000 per year<sup>18,19</sup>.
- No transmission after achieving EOT: Unlike previous Warwick gHAT model variants, once the EOT threshold is met we set transmission to zero in subsequent years and therefore no further new infections is possible. Previously infected people can still be identified and reported (although there are typically extremely few reported cases at that point).

# 113 S4. PRIME-NTD criteria

<sup>114</sup> It has been recommended that good modelling practises should meet the five key principles relating to communica-<sup>115</sup> tion, quality and relevance of analyses – known as Policy-Relevant Items for Reporting Models in Epidemiology of

<sup>116</sup> Neglected Tropical Diseases (PRIME-NTD)<sup>23</sup>. We present how these PRIME-NTD criteria have each been addressed

in Table S3.

Table S3: PRIME-NTD criteria fulfillment. We summarise how the NTD Modelling Consortium's "5 key principles of good modelling practice" have been met in the present study.

Principle and what has been done to satisfy the principle?	Where in the manuscript is this described?	
1. Stakeholder engagement	Authorship list	
This study was lead by modellers and guided by members of the national	1	
sleeping sickness control programme in DRC (PNLTHA-DRC) – coauthors		
E Mwamba Miaka and S Chancy PNLTHA-DRC have contributed to im-		
proved modeller understanding of the epidemiological data and changes to		
the programme over time and in different geographic regions both of which		
impacted model fitting over several rounds of revision (via in person meet		
ings and amail) The GUI (and several variants of it) was designed in con-		
ings and email). The OOI (and several variants of it) was designed in con-		
Junction with FNLTHA-DKC to improve communication of the moderning		
outputs to non-modellers. It has been relined through various in-person		
meetings with different collaborators with the goal of providing understand-		
able, policy-relevant outputs as well as scientific communication; over 20		
non-modellers have had opportunities to interact with and provide feedback		
on the GUI during development.		
2. Complete model documentation	See Section S1 above in this document and	
Full model (including the fitting code) and documentation are available	access the code via ProjOSF	
through Open Science Framework (OSF). The model is fully described in		
this SI and in the fitting study of Crump <i>et al</i> <sup><math>1</math></sup> .		
3. Complete description of data used	Posteriors available at FittingOSF	
The data used for fitting were described in detail in Crump <i>et al</i> <sup><math>1</math></sup> . Posteriors		
used for the projections presented here are available on our OSF page.		
4. Communicating uncertainty		
Structural uncertainty:	See Methods section in main text.	
The variant of the model presented here ("Model 4") was chosen as it had		
good support compared to other plausible model structures when fitting to		
data sets from Yasa Bonga and Mosango health zones in $DRC^2$ and in the		
Mandoul focus Chad <sup>4</sup>		
Hundour rocus, chud		
Parameter uncertainty:	See Methods section in main text and	
In the fitting study <sup>1</sup> key model parameters were fitted in an MCMC frame-	Crump <i>et al</i> <sup><math>1</math></sup> , and posterior files are avail-	
work by utilising regional data, we used these posterior parameter sets to	able at FittingOSF. Sensitivity analysis	
simulate forward projections in the present study. Sensitivity analysis was	for VC in Section S2.1 above and in GUI.	
performed on the assumed impact of tsetse reduction through vector control		
(VC) with 60% and 90% reductions presented in addition to the default 80%		
assumption.		
Prediction uncontainty	Saa Figuras 1 and 2 in the main text and	
Frediction uncertainty.	mono in CUL	
Here, we represent uncertainty in our results in various ways - (1) by provid-	maps m GOT.	
ing box and whisker plots for predictions (median, 50% and 95% prediction		
intervals), (ii) by utilising probability maps (likelihood of meeting EOI goal		
by 2030) in addition to median year of EO1 maps, and (iii) by providing		
prediction intervals for EOT years in the hoover feature of our GUI.		
5. Iestable model outcomes	Predictions presented in main text Figure 1	
Predictions presented here include measurable, and routinely reported out-	and in the GUI. Model code and posteri-	
comes such as active and passive case reporting by year. Outputs in the	ors which could be used for validation are	
GUI can be compared to new case data as it becomes available. Our predic-	available at ProjOSF and FittingOSF.	
tions are dependant on the coverage of active screening each year and are		
expected to perform better when the actual screening coverage is similar to		
that assumed for predicting. In the future we plan to validate the predictions		
based on at least two years of new case data to assess model performance.		

<sup>1</sup> Hyperlink ProjOSF with full address: https://osf.io/jza27/?view\_only=526344c12324492083db1e49c76136af.
<sup>2</sup> Hyperlink FittingOSF with full address: https://osf.io/ck3tr/?view\_only=526344c12324492083db1e49c76136af.
<sup>3</sup> Hyperlink GUI with with full address: https://hatmepp.warwick.ac.uk/projections/vl

# **118** References

- Crump RE, Huang CI, Knock ES, Spencer SEF, Brown PE, Mwamba Miaka E, et al. Quantifying epidemiological drivers of *gambiense* human African trypanosomiasis across the Democratic Republic of Congo.
   PLOS Computational Biology. 2021;17:1–23.
- Rock KS, Torr SJ, Lumbala C, Keeling MJ. Quantitative evaluation of the strategy to eliminate human African
   trypanosomiasis in the Democratic Republic of Congo. Parasites & Vectors. 2015;8:532.
- 1243Rock KS, Torr SJ, Lumbala C, Keeling MJ. Predicting the impact of intervention strategies for sleeping sick-125ness in two high-endemicity health zones of the Democratic Republic of Congo. PLOS Neglected Tropical126Diseases. 2017;11:e0005162.
- Mahamat MH, Peka M, Rayaisse Jb, Rock KS, Toko MA, Darnas J, et al. Adding tsetse control to medical
   activities contributes to decreasing transmission of sleeping sickness in the Mandoul focus (Chad). PLOS
   Neglected Tropical Diseases. 2017;11:e0005792.
- OCHA Office for the Coordination of Humanitarian Affairs. Journees Nationales de Vaccination (JNV) ac tivities de vaccination supplementaire, RDC. (accessed May 2016). Available from: https://data.
   humdata.org/dataset/rdc-statistiques-des-populations.
- The World Bank. Data: Democratic Republic of Congo. (accessed 2015). Available from: https://data.
   worldbank.org/country/congo-dem-rep?view=chart.
- <sup>135</sup> 7 Rogers DJ. A general model for the African trypanosomiases. Parasitology. 1988;97:193–212.
- <sup>136</sup> 8 Checchi F, Filipe JAN, Barrett MP, Chandramohan D. The natural progression of gambiense sleeping sickness: what is the evidence? PLOS Neglected Tropical Diseases. 2008;2:e303.
- Checchi F, Funk S, Chandramohan D, Haydon DT, Chappuis F. Updated estimate of the duration of the meningo-encephalitic stage in gambiense human African trypanosomiasis. BMC Research Notes.
   2015;8:292.
- Mpanya A, Hendrickx D, Vuna M, Kanyinda A, Lumbala C, Tshilombo V, et al. Should I get screened for
   sleeping sickness? A qualitative study in Kasai province, Democratic Republic of Congo. PLOS Neglected
   Tropical Diseases. 2012;6:e1467.
- Checchi F, Chappuis F, Karunakara U, Priotto G, Chandramohan D. Accuracy of five algorithms to diagnose
   gambiense human African trypanosomiasis. PLOS Neglected Tropical Diseases. 2011;5:e1233.
- Davis S, Aksoy S, Galvani AP. A global sensitivity analysis for African sleeping sickness. Parasitology.
   2010;138:516–526.
- 14813Ravel S, Grebaut P, Cuisance D, Cuny G. Monitoring the developmental status of *Trypanosoma brucei*149gambiense in the tsetse fly by means of PCR analysis of anal and saliva drops. Acta Tropica. 2003;88:161–150165.
- World Health Organization & WHO Expert Committee on the Control and Surveillance of Human African
   Trypanosomiasis (2013: Geneva, Switzerland). Control and surveillance of human African trypanosomiasis:
   report of a WHO expert committee. WHO technical report series; no. 984. World Health Organization; 2013.
- Clausen PH, Adeyemi I, Bauer B, Breloeer M, Salchow F, Staak C. Host preferences of tsetse (Diptera:
   Glossinidae) based on bloodmeal identifications. Medical and Veterinary Entomology. 1998;12:169–180.
- Lumbala C, Simarro PP, Cecchi G, Paone M, Franco JR, Kande Betu Ku Mesu V, et al. Human African
   trypanosomiasis in the Democratic Republic of the Congo: disease distribution and risk. International Journal
   of Health Geographics. 2015;14:20.
- <sup>159</sup> 17 Simarro PP, Cecchi G, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global
   <sup>160</sup> mapping of neglected tropical diseases. International Journal of Health Geographics. 2010;9:57.

- 18 Rock KS, Ndeffo-Mbah ML, Castaño S, Palmer C, Pandey A, Atkins KE, et al. Assessing strategies against
   gambiense sleeping sickness through mathematical modeling. Clinical Infectious Diseases. 2018;66:S286–
   S292.
- Castaño MS, Ndeffo-Mbah ML, Rock KS, Palmer C, Knock E, Mwamba Miaka E, et al. Assessing the impact
   of aggregating disease stage data in model predictions of human African trypanosomiasis transmission and
   control activities in Bandundu province (DRC). PLOS Neglected Tropical Diseases. 2020;14:e0007976.
- Courtin F, Camara M, Rayaisse JB, Kagbadouno M, Dama E, Camara O, et al. Reducing human-tsetse contact
   significantly enhances the efficacy of sleeping sickness active screening campaigns: a promising result in the
   context of elimination. PLOS Neglected Tropical Diseases. 2015;9:e0003727.
- Tirados I, Esterhuizen J, Kovacic V, Mangwiro TNC, Vale GA, Hastings I, et al. Tsetse control and gambian sleeping sickness; implications for control strategy. PLOS Neglected Tropical Diseases. 2015;9:1–22.
- Tirados I, Hope A, Selby R, Mpembele F, Miaka EM, Boelaert M, et al. Impact of tiny targets on *Glossina fuscipes quanzensis*, the primary vector of human African trypanosomiasis in the Democratic Republic of the Congo. PLOS Neglected Tropical Diseases. 2020;14:1–20.
- Behrend MR, Basáñez MG, Hamley JID, Porco TC, Stolk WA, Walker M, et al. Modelling for policy: The
   five principles of the Neglected Tropical Diseases Modelling Consortium. PLOS Neglected Tropical Diseases.
   2020;14:e0008033.